Pivotal's scientific team is composed of respected researchers with numerous other drugs in clinical trials throughout the world. Our business team includes experienced professionals who have managed drug development through clinical trials to FDA approval. The Advisory Board consist of distinguished scientists and scientist/businessmen who are actively assisting Pivotal Biosciences. The clinical, regulatory and business development functions of Pivotal Biosciences are provided by Catalyst Pharmaceutical Research, L.L.C., Pasadena, California.

Business Team

Former Director of investment banking firm SG Cowen, active in venture capital as a member of the Tech Coast Angels.

President of Catalyst Pharmaceutical Research LLC, specializing in designing and managing FDA submissions, clinical trials and strategic product licensing.

Senior medical technology analyst at Lazard, a global institutional equity research and investment banking firm.

20 year executive veteran in biotech R&D, with successful commercialization experience of biopharmaceuticals at Egea BioSciences, Immune Response and other biotechnology companies.

Science Team

Developed a novel method to target necrotic cells in human cancers, published over 120 articles on cancer research. Dr. Epstein currently has two cancer drugs in U.S. clinical trials with Peregrine Pharmaceuticals, Inc.

World's foremost authority on therapeutic compounds from snake venom. With over 120 published articles, a clinical trial based on his novel compound from snake venom to treat blood clots is under way at Nuvelo, Inc.

Pivotal's Scientific and Business Advisory Board consists of highly respected individuals in their scientific fields who provide an invaluable resource to Pivotal through the R&D process. Their collective experience includes domain expertise in the development and testing of new therapies for cancer, immunotherapy and vaccine development, infectious diseases, pharmacology, biophysics and structural biology at the USC Keck School of Medicine, M.D. Anderson Cancer Center/University of Texas, and The Mayo Clinic.

Scientific and Business Advisory Board

An expert on the development and testing of new therapies for cancer, especially in new formulations of IL-2 and methods to improve its half-life and delivery into patients.

A noted investigator of T-cell immunity who has devoted a large part of her career to the study and use of IL-2 for the treatment of cancer.

Dr. Martin's distinguished career has included positions at several entities within the National Institutes of Health; the Weizmann Institute of Science, the Max-Planck Institut fur Biochemie; Scientific Director, National Institute on Aging and Director, Gerontology Research Center; and Senior Vice President for Scientific Affairs, FibroGen, Inc. He has also served as Adjunct Professor, Stanford University, and is a member of the Editorial Board, Cell Biology and Toxicology.

An experienced biotechnology executive who has both taken drugs through pre-clinical and clinical trials and has been involved with the financing of several biotech ventures.

Biotechnology entrepreneur and prominent scientist who has built a company from startup to a successful enterprise.